Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Patents (Class 424/145.1)
  • Patent number: 11518814
    Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: December 6, 2022
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Michael Jensen, Rebecca Gardner
  • Patent number: 11492386
    Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Andrew H Korytko, Yanfei L Ma, Amita Datta-Mannan, Victor H Obungu
  • Patent number: 11492396
    Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 8, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
  • Patent number: 11480574
    Abstract: The present invention relates to reagent kits for in vitro measurement of YKL-40 and MASP2 and diagnosis of hepatocarcinoma of a test individual.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: October 25, 2022
    Inventor: Biaoyang Lin
  • Patent number: 11472856
    Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 18, 2022
    Assignee: Torque Therapeutics, Inc.
    Inventors: Ferdinando Pucci, Thomas Lars Andresen, Douglas Scott Jones, Ulrik Nielsen, James Andrew Rakestraw
  • Patent number: 11458129
    Abstract: In some embodiments, methods of inhibiting, ameliorating, reducing the severity of, treating, reducing the likelihood of, or preventing social isolation stress or symptoms thereof in a subject in need thereof are described. In some embodiments, methods of determining a risk of social isolation stress in a subject are described.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 4, 2022
    Assignee: California Institute of Technology
    Inventors: David J. Anderson, Moriel Zelikowsky, Andrea Choe
  • Patent number: 11419871
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: August 23, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • Patent number: 11421025
    Abstract: The present invention provides a vaccine against IL-17A, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to SEQ ID NO: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving IL-17A as an aggravation factor, and the like.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: August 23, 2022
    Assignee: OSAKA UNIVERSITY
    Inventors: Hiroshi Koriyama, Hironori Nakagami, Ryuichi Morishita
  • Patent number: 11400054
    Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C?O)-alkyl, —(C?O)-aryl, —(C?O)-alkyl-aryl, —(C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C?O)—CH3 or —(C?O)—NH2.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 2, 2022
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kuo-Kuei Huang, I-Hong Pan, Shu-Fang Wen, Meng-Nan Lin, I-Huang Lu, Zong-Keng Kuo, Chu-Hsun Lu, Tze-Chung Lee, Ya-Yan Yang, Jia-Horng Liaw, Pei-Hsin Lin
  • Patent number: 11389509
    Abstract: The present disclosure relates to methods of treating social dysfunction neurological disorders in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity, and to a method of treating seizures in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity. In some embodiments, the compound is IFN-?.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: July 19, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Anthony J. Filiano, Jonathan Kipnis
  • Patent number: 11359011
    Abstract: The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory age—iAge, the cardiovascular age—cAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 14, 2022
    Assignee: Edifice Health, Inc.
    Inventor: David Furman
  • Patent number: 11345759
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 31, 2022
    Assignees: CSL Behring GmbH, CSL Ltd
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 11319375
    Abstract: Disclosed herein are methods for treating subjects having rheumatoid arthritis (RA) with a human anti-interleukin 6 (IL-6) antibody, or antigen-binding portion thereof.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 3, 2022
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Anita Boyapati, Neil Graham, Toshio Kimura, Jérôme Msihid
  • Patent number: 11306289
    Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 19, 2022
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Cassian Yee
  • Patent number: 11299537
    Abstract: The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: April 12, 2022
    Assignee: FIBROGEN, INC.
    Inventors: Enrique Brandan, David Gonzalez
  • Patent number: 11279753
    Abstract: The invention provides a method of treating a disease or disorder in a subject by inducing a TGF alpha immune response or by administering an anti-TGF-alpha antibody or a biologically active fragment thereof. The TGF-alpha immune response is induced using a TGF-alpha polypeptide or biologically active fragment, a vaccine, a genetic construct or a transformed cell, for example.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: March 22, 2022
    Inventor: George J. Todaro
  • Patent number: 11279755
    Abstract: Methods for treating eye diseases such as dry eye disease (DED) and age-related macular degeneration (AMD) using an IL-20 antagonist that blocks the signaling pathway mediated by IL-20, for example, an antibody that binds IL-20 or an IL-20 receptor.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 22, 2022
    Assignee: LBL Biotechnology, Inc.
    Inventor: Ming-Shi Chang
  • Patent number: 11253540
    Abstract: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: February 22, 2022
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Tomochika Kisukeda, Yasuhiro Goto, Yuichi Chikaraishi, Takahiro Hatanaka
  • Patent number: 11248038
    Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: February 15, 2022
    Assignee: University of Mississippi Medical Center
    Inventors: Gene L. Bidwell, III, Alejandro R. Chade
  • Patent number: 11226341
    Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 18, 2022
    Assignee: Genentech, Inc.
    Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
  • Patent number: 11220690
    Abstract: The present invention relates to a new formulation of the oligonucleotide of SEQ ID NO:1.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: January 11, 2022
    Assignee: Atlantic Pharmaceuticals (Holdings) LTD
    Inventors: Toby Wilson Waterworth, Lorin Johnson, Janette Thomas, Michael Webb
  • Patent number: 11220554
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 11, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • Patent number: 11208474
    Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: December 28, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Dennis Fitzgerald, Newman Yeilding, Jay Siegel
  • Patent number: 11193934
    Abstract: A method for increasing the veracity of classification by detecting protein YKL-40 and MASP2 levels in the samples, comprises detecting the content of the YKL-40 and MASP2 in the samples; the ratio of the content of YKL-40 to the that of MASP2 acted as variable, receiving the ROC curve according to the sensitivity and specialty of the difference threshold value to the diagnosis for the cancer, calculating an area under the curve AUC; classifying the samples according to the value of the AUC, sensitivity and specialty. And a kit for detecting the protein YKL-40 and MASP2 levels in the samples.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: December 7, 2021
    Inventor: Biaoyang Lin
  • Patent number: 11191808
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting rejection of transplanted cells including a high mobility group box 1 A domain (HMGB1A) as an active ingredient. The use of the pharmaceutical composition can minimize immunological rejection, which may occur upon cell transplantation, and increase the success rate of cell transplantation.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: December 7, 2021
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Dong Yun Lee, Yong Hwa Hwang, Min Hyung Lee
  • Patent number: 11191831
    Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: December 7, 2021
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Patent number: 11180549
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 23, 2021
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, Inc
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 11174321
    Abstract: The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 16, 2021
    Assignee: CSL LIMITED
    Inventors: Con Panousis, Karlheinz Peter, Hamid Hosseini, Yung-Chih Chen
  • Patent number: 11175292
    Abstract: The present invention provides an anti-human hemoglobin monoclonal antibody or an antibody kit for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample with ease, and an insoluble carrier particle to which the monoclonal antibody is immobilized, and a measurement reagent and a measurement method for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample using the same. The anti-human hemoglobin monoclonal antibody of the present invention does not react to free hemoglobin or free haptoglobin which is not formed in a complex, but specifically reacts to a hemoglobin-haptoglobin complex when the antibody is immobilized to an insoluble carrier particle and used.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 16, 2021
    Assignee: EIKEN KAGAKU KABUSHIKI KAISHA
    Inventors: Ryota Yasui, Megumi Yui, Mitsuru Makinodan, Yasuhiro Seki, Chisa Sakanishi
  • Patent number: 11168147
    Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 9, 2021
    Assignee: NOVARTIS AG
    Inventors: Maximilian Aigner, Alexander Wolfgang Koch, Markus Waldhuber
  • Patent number: 11160873
    Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: November 2, 2021
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research Institute
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Patent number: 11155611
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 26, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Stefan Wawersik, Yung Chyung, Micah Webster
  • Patent number: 11136402
    Abstract: This document provides antibodies against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) short, and more particularly to humanized TRAILshort antibodies that can neutralize TRAILshort. For example, materials and methods for using one or more humanized TRAILshort antibodies to induce apoptosis (e.g., via TRAIL mediated cell death, natural killer (NK) cytotoxicity, and/or CD8+ T cell killing) are provided.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 5, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Andrew D. Badley
  • Patent number: 11135178
    Abstract: The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, generation, or maintenance in animals.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 5, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventor: Rajan Sah
  • Patent number: 11078270
    Abstract: The invention relates to negative functional modulators of erythropoietin (EPO) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia A and B, von Willebrand disease, angiodysplasia, proliferative disorders and neurological diseases characterized in their pathogenesis by primary neuroinflammation and/or neuroinflammation secondary to other causes. Such modulators are anti-EPO antibodies and their derivatives: anti-EPO receptor antibodies (EPOR), antisense oligonucleotides, decoy DNA, decoy RNA, ribozyme, antagomir, shRNA, LNA and/or siRNAs that inhibit the expression of the gene encoding EPO or EPOR.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 3, 2021
    Assignee: ANDREMACON S.R.L.
    Inventors: Giovanni Marfia, Stefania Elena Navone, Giuseppe Scalvini, Laura Riboni, Rolando Campanella
  • Patent number: 11066481
    Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: July 20, 2021
    Assignees: The Regents of the University of California, Pfizer, Inc.
    Inventors: Thomas Mikita, Lauren K. Ely, Huilan Gao, Yun Kim, Isaac J. Rondon, Tovo David, Shaun R. Coughlin
  • Patent number: 11059905
    Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 13, 2021
    Assignee: Prothix B.V.
    Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
  • Patent number: 11046757
    Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: June 29, 2021
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • Patent number: 11040102
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventor: Timothy David Osslund
  • Patent number: 10995365
    Abstract: Compositions, devices, systems and methods for increasing the signal to noise ratio (SNR) and/or enhancing photoprotection in an illuminated analytical reaction by addition of one or more signal detection assay (SDA)-enhancing agents to the reaction mixture.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: May 4, 2021
    Inventors: Stephen Yue, Andrei Fedorov, Gene Shen, Sophia Wu
  • Patent number: 10975168
    Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 13, 2021
    Assignee: GENENTECH, INC.
    Inventors: Shahram Misaghi, John B. Lowe, Bradley Richard Snedecor
  • Patent number: 10968282
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 6, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Patent number: 10962532
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: March 30, 2021
    Assignee: Prognosys Biosciences, Inc.
    Inventor: Mark S. Chee
  • Patent number: 10953069
    Abstract: The present disclosure provides a method for treating lung cancer in a subject in need of such treatment includes administering to the subject a pharmaceutical composition. The pharmaceutical composition includes an effective amount of a betanodavirus B2 protein or a fragment thereof, or a nucleic acid molecule encoding the betanodavirus B2 protein or the fragment and optionally a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 23, 2021
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Jiann-Ruey Hong, Hsuan-Wen Chiu, Yu-Chin Su
  • Patent number: 10954297
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Patent number: 10954303
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOGEN MA INC.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Patent number: 10912605
    Abstract: A facet joint surgical tool for treating a facet joint synovial cyst includes rotatable members disposed side-by-side through a minimally invasive sheath and rotatable to reconfigure distal end portions between a facet joint penetration configuration with a tissue piercing tip and a facet joint retraction configuration. Facet joint synovial cysts located to an anterior side of the facet joint are treated by a posterior approach with access to the cyst through the facet joint retracted by the surgical tool. Facet joint synovial cysts located to a posterior side of the facet joint are treated by direct access from a posterior approach.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: February 9, 2021
    Assignee: Thixos LLC
    Inventors: Murray David Solsberg, Douglas Preston Beall, Ryan Erich Dean
  • Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • Patent number: 10899827
    Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 26, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Joshua Rabbani, James J. Donegan
  • Patent number: 10882905
    Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders, in particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 5, 2021
    Assignee: AB2 BIO SA
    Inventors: Greg Del Val, Eduardo Schiffrin